Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).
Journal Article (Journal Article;Review)
Medulloblastoma, the most common malignancy of childhood, was originally shown to be sensitive to cyclophosphamide in 1981. We have used combined laboratory and clinical investigations to demonstrate the synergy of cyclophosphamide and vincristine in the treatment of this tumor, the therapeutic gain associated with escalation of the dosage of cyclophosphamide, the consequence of and mechanisms underlying resistance of medulloblastoma to cyclophosphamide, the emerging importance of the neuraxis as a site of relapse of medulloblastoma, and newer approaches, including intrathecal 4-hydroperoxycyclophosphamide and busulfan, to treat neuraxis disease. These studies serve as a paradigm for laboratory-clinical translational research.
Full Text
Duke Authors
Cited Authors
- Friedman, HS; Bigner, SH; Bigner, DD
Published Date
- 1995
Published In
Volume / Issue
- 24 / 1
Start / End Page
- 103 - 108
PubMed ID
- 8523066
International Standard Serial Number (ISSN)
- 0167-594X
Digital Object Identifier (DOI)
- 10.1007/BF01052667
Language
- eng
Conference Location
- United States